Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia (original) (raw)
Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
Tikva Carrick
Bioorganic & Medicinal Chemistry Letters, 2010
View PDFchevron_right
Targeting Dopamine D 3 and Serotonin 5-HT 1A and 5-HT 2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies
Stefania Butini
Journal of Medicinal Chemistry, 2014
View PDFchevron_right
SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug
Arnoud Herremans
Neuropsychopharmacology, 2007
View PDFchevron_right
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
Adrian Newman-Tancredi
Psychopharmacology, 2011
View PDFchevron_right
Pyrrolo[1,3]benzothiazepine-Based Serotonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structure−Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents
maria assunta di cesare
Journal of Medicinal Chemistry, 2004
View PDFchevron_right
Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia
Vivek Asati
In Silico Pharmacology
View PDFchevron_right
Newer molecules in the treatment of schizophrenia: A clinical update
Abhishek Ghosh
Indian Journal of …, 2011
View PDFchevron_right
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
Adrian Newman-Tancredi
Journal of Pharmacology and Experimental Therapeutics, 2007
View PDFchevron_right
Serotonin receptors : their key role in drugs to treat schizophrenia
Yasuhiro Kaneda
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
View PDFchevron_right
Canonical and Non-Canonical Antipsychotics’ Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia
Andrea de Bartolomeis
International Journal of Molecular Sciences
View PDFchevron_right
Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626
Robert Mach, Jinbin Xu
Bioorganic & Medicinal Chemistry, 2010
View PDFchevron_right
Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior
Sindu Ros
Journal of Medicinal Chemistry, 2008
View PDFchevron_right
F15063, a compound with D 2 /D 3 antagonist, 5-HT 1A agonist and D 4 partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia
M. Kleven, Ronan Depoortere, Adrian Newman-Tancredi, Adrian Newman-Tancredi, Agnès Auclair
British Journal of Pharmacology, 2007
View PDFchevron_right
F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
Ronan Depoortere, Adrian Newman-Tancredi, Agnès Auclair
Naunyn-Schmiedeberg's Archives of Pharmacology, 2007
View PDFchevron_right
Investigational dopamine antagonists for the treatment of schizophrenia
Tae-Youn Jun
Expert opinion on investigational drugs, 2017
View PDFchevron_right
Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands
Ferran Sanz
Bioorganic & Medicinal Chemistry Letters, 2009
View PDFchevron_right
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors
Gilda Neves
Bioorganic & Medicinal …, 2010
View PDFchevron_right
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
jeffrey lieberman
View PDFchevron_right
S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo
Nitza Thomasson
Journal of Pharmacology and Experimental Therapeutics, 2007
View PDFchevron_right
Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores
Seth Ablordeppey
Bioorganic & Medicinal Chemistry, 2016
View PDFchevron_right